Notably, treatment with EPO is associated with multiple adverse events, such as hypertension, nausea, headache, thromboembolic events, polycythemia, intracerebral hemorrhage, brain edema, and death, particularly when administered systemically and chronically or at a higher dose [72,73]. The gene discussed is EPO; the disease is hypertensive disorder.